According to FutureWise analysis the market for Angiotensin Converting Enzyme (ACE) Inhibitors in 2023 was US$ 3.63 billion, and is expected to reach US$ 5.42 billion by 2031 at a CAGR of 5.10%.
Angiotensin-Converting Enzyme (ACE) inhibitors are a class of medications designed to relax veins and arteries, effectively lowering blood pressure. They function by inhibiting an enzyme that plays a crucial role in the production of angiotensin II, a hormone that causes the narrowing of blood vessels. This narrowing can result in higher blood pressure, putting extra strain on the heart.
Angiotensin II circulates in the bloodstream and has significant effects on the cardiovascular system, primarily through the constriction of blood vessels. This narrowing can result in increased blood pressure and workload for the heart, particularly in cases where the heart has been weakened due to conditions such as a heart attack or heart failure. By inhibiting the production of angiotensin II, ACE inhibitors effectively prevent this constriction, leading to a reduction in blood pressure and decreased energy expenditure by the heart with each heartbeat.
Originally, ACE inhibitors were primarily used to treat high blood pressure (hypertension) by promoting the relaxation of constricted blood vessels. However, as newer and effective agents became available for hypertension management, the therapeutic use of ACE inhibitors expanded. They became particularly beneficial for individuals with weakened heart muscles, commonly associated with heart failure, which is often marked by elevated levels of angiotensin II in the blood. Studies have shown that administering ACE inhibitors to patients with heart failure not only delays the onset of symptoms but also reduces heart failure-related mortality and the frequency of hospitalizations. Additionally, ACE inhibitors have been investigated for their efficacy in individuals who have experienced heart attacks, even if they are not yet exhibiting symptoms of heart failure.
FutureWise Market Research has published a report that provides an insightful analysis of Angiotensin Converting Enzyme (ACE) Inhibitors Market trends that are affecting the overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=10920&type=requestsample
Angiotensin Converting Enzyme (ACE) Inhibitors Market Segmentation:
By Drug
- Lisinopril
- Ramipril
- Enalapril
- Benazepril
- Fosinopril
- Captopril
- Moexipril
- Others
By Application
- Heart Failure
- Hypertension
- Diabetes
- Heart Attack
- Chronic Kidney Disease
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- E-Commerce Websites
- Online Drug Stores
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Angiotensin Converting Enzyme (ACE) Inhibitors Market:
- Abbott
- Bausch Health Companies Inc.
- AbbVie Inc.
- Pfizer Inc.
- DAIICHI SANKYO COMPANY, LIMITED
- Novartis AG
- Merck KGaA
- La Jolla Pharmaceutical Company
- Quantum Genomics
- AstraZeneca
- Johnson and Johnson Services, Inc.
- Eli Lilly and Company
- Par Pharmaceutical
- Sanofi
- Bristol-Myers Squibb Company
- Sandoz AG
- Mayo Foundation for Medical Education and Research (MFMER)
- Bayer AG
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=10920&license=multi
**Objectives of this Study: **
- To provide a comprehensive analysis of the Angiotensin Converting Enzyme (ACE) Inhibitors Market By Drug, By Application, By Distribution Channel and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
